Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

J&J’s oncology and immunology segments shine in Q3 2023

By Brian Buntz | October 17, 2023

J&JJohnson & Johnson has announced its first earnings following its decision to rebrand its pharma segment as Johnson & Johnson Innovative Medicine in September. In the third quarter of 2023, the company reported sales growth of 6.8%, amounting to $21.4 billion. 

The bestseller for the company was Stelara with sales amounting to $2.864 billion.

J&J’s oncology segment also continues to be a strong performer. Within oncology, the multiple myeloma therapy Darzalex took the spotlight with quarterly sales hitting $2.5 billion. Next in line were Imbruvica, primarily used to treat certain types of B-cell malignancies, with sales of $808 million and Erleada, a prostate cancer drug, with $631 million in sales.

Other strong performers included the blood thinner Xarelto with sales of $625 million and, Opsumit, a treatment for pulmonary arterial hypertension (PAH), which contributed $490 million to J&J’s bottom line.

J&J sales growthDuring the earnings call, Joaquin Duato, chairman and CEO, highlighted the company’s confidence in its portfolio, stating, “We are very pleased with the performance of our immunology business, especially Tremfya with 25.1% growth in the quarter.”

The company projected in 2021 that Tremfya would hit $5 billion in sales. “Now you can see clearly that we’re going not only to meet that but to clearly exceed that benchmark for Tremfya,” Duato said. 

He described Tremfya, Erleada, and Uptravi, along with long-acting injectables, as “key assets,” but gave special credit to Darzalex, noting it “continues to have a tremendous trajectory gaining share in first line.”

The company is aiming to have its pharma division hit a $57 billion target by 2025

When it came to the fastest growth, Spravato was at the front of the pack with a 82.1% growth rate. Other drugs with swift growth included Erleada (28.7%), Darzalex (21.8%), Edurant/rilpivirine (21.0%), and Uptravi (20.7%).

pie chartOn the flip side, some products experienced significant sales drops, with the COVID-19vaccine leading this decline at -91.5%, followed by Zytig /abiraterone acetate (-53.0%), Remicade (-17.4%), Imbruvica (-11.3%), and Xarelto (-9.4%).

The Innovative Medicine segment witnessed a growth of 5.1% compared to its 2022 figures. Its MedTech segment fared better, posting 10.0% growth over the previous year. One factor driving growth of the segment was J&J’s acquisition of Abiomed, which drove 4.6% to the operational sales growth. Strong sales of electrophysiology products, wound closure products, and contact lenses were also contributors to the MedTech business’s success.

Toward the end of the earnings call, Duato emphasized the company’s future trajectory, noting that the company is “excited about the growth profile of our Innovative Medicine group as we head into the second half of the decade.” Duato expressed confidence in their strong pipeline, especially in immunology and oncology.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE